Ondine Biomedical (LON:OBI) Sets New 52-Week High Following Insider Buying Activity

Ondine Biomedical Inc. (LON:OBI)’s stock price hit a new 52-week high during mid-day trading on Friday following insider buying activity. The company traded as high as C$13.30 and last traded at C$13.30, with a volume of 209400 shares changing hands. The stock had previously closed at C$12.50.

Specifically, insider Carolyn Cross acquired 149,225 shares of Ondine Biomedical stock in a transaction dated Monday, February 3rd. The stock was bought at an average cost of C$13.00 per share, for a total transaction of C$1,939,925.00.

Ondine Biomedical Price Performance

The firm has a market capitalization of C$3.69 billion, a price-to-earnings ratio of -443.33 and a beta of 0.10. The company’s 50 day moving average is C$9.63 and its 200-day moving average is C$8.14. The company has a current ratio of 0.80, a quick ratio of 8.26 and a debt-to-equity ratio of 1,847.37.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.